The role of human papillomavirus (HPV) virus as the cause of cervical cancer has long been established. The infectious etiology and long latency period made a prevention, screening, mitigation, and treatment paradigm typically implemented for communicable diseases a rational strategy for the worldwide eradication of cervical cancer (Fig. 1). 1 The development of an effective and safe vaccine against the HPV virus in the early 2000s offered the last key component necessary for this plan to be enacted. Before the availability of the HPV vaccine, the disease had already become uncommon in many high-income countries (HICs) through widespread cytologic screening programs and the availability of treatment for preinvasive disease. However, 14 years after the vaccine was approved for use in the United States, cervical cancer continues to be the most commonly diagnosed cancer among women in 28 countries and the leading cause of cancer death in 42 countries, including the majority in sub-Saharan Africa and Southeastern Asia. 2 In every setting worldwide, cervical cancer disproportionately affects poor, vulnerable, and minority populations. Those women most susceptible to this disease are those with the fewest resources to contend with it after a diagnosis. In this issue of Cancer, Gatti et al 3 present their assessment of the worldwide availability of health services relevant to cervical cancer. Despite clearly defined comprehensive packages, significant deficits were identified. Only 21% and 19.1% of nations provided all required interventions to control cervical cancer from their "Essential Cancer Package" and "Primary Care Package," respectively. Access to items within the packages unsurprisingly tracked with income. A complex, multifaceted collection of barriers contributes to this persistent and growing discrepancy between the vision of cervical cancer elimination and the reality on the ground. Implementation of the components evaluated in the 2 packages, including vaccination, screening, treatment, and monitoring, is unsatisfactory in all resource settings, but particularly tenacious obstacles persist in low-resource settings. We have been globally complacent about the impact of disparities in health care spending, access to care, and resource allocation and their impact on cervical cancer prevention, screening, and treatment across HICs versus low-income countries (LICs). These cataclysmic inequities have been often and well described. 4,5 The acceptability and delivery of HPV vaccination have been slower than anticipated, particularly in lower income countries. Among 55 vaccine projects and 8 national programs in 37 lower middle-income countries (LMICs) started between January 2007 and 2015, only 70% achieved first-dose coverage. 6 Even when the financial hurdles associated with vaccination can be overcome, written parental consent results in lower coverage, and fears of adverse effects and a lack of project awareness and goals require interactive communication to dispel rumors. Challenges in screening in lower inc...